Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Brada, M, Judson, I, Beale, P, Moore, S, Reidenberg, P, Statkevich, P, Dugan, M, Batra, V, Cutler, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362937/
https://www.ncbi.nlm.nih.gov/pubmed/10576660
http://dx.doi.org/10.1038/sj.bjc.6690802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362937/
https://www.ncbi.nlm.nih.gov/pubmed/10576660
http://dx.doi.org/10.1038/sj.bjc.6690802

Ejemplares similares